Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a review.
The opioid growth factor (OGF)-OGF receptors (OGFr) axis plays an important role in the homeostasis and re-epithelialization of the mammalian cornea. This tonically active growth regulatory inhibitory pathway is involved in cell replication, and the endogenous neuropeptide OGF targets cyclin-dependent kinase inhibitors, p16 and/or p21. Blockade of OGF-OGFr interfacing by systemic or topical administration of opioid antagonists such as naltrexone (NTX) results in accelerated DNA synthesis, cell replication, and tissue repair. Molecular manipulation of OGFr using sense constructs delayed corneal re-epithelialization, whereas antisense constructs accelerated repair of the corneal surface. Corneal keratopathy, a significant complication of diabetes mellitus, is manifested by delays in corneal re-epithelialization following surgery, injury, or disease. Tissue culture studies have shown that addition of NTX stimulates DNA synthesis and explant outgrowth of rabbit corneal epithelium, whereas OGF depresses DNA synthesis and explant outgrowth in a receptor-mediated manner. NTX accelerated corneal re-epithelialization in organ cultures of human and rabbit cornea. Systemic application of NTX to the abraded corneas of rats, and topical administration of NTX to the injured rabbit ocular surface, increased re-epithelialization. Systemic injections or topical administration of NTX facilitates re-epithelialization of the cornea in diabetic rats. Given the vital role of the corneal epithelium in maintaining vision, the frequency of corneal complications related to diabetes (diabetic keratopathy), and the problems occurring in diabetic individuals postoperatively (e.g., vitrectomy), and that conventional therapies such as artificial tears and bandage contact lenses often fail, topical application of NTX merits clinical consideration.
McLaughlin
Patricia J
PJ
Department of Neural & Behavioral Sciences, The Pennsylvania State University College of Medicine, Hershey, PA, USA.
Sassani
Joseph W
JW
Klocek
Matthew S
MS
Zagon
Ian S
IS
D000701:Analgesics, Opioid / Q000378:metabolism*; D000818:Animals; D003316:Corneal Diseases / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D048909:Diabetes Complications / Q000150:complications; D004195:Disease Models, Animal; D004848:Epithelium / Q000187:drug effects; D006801:Humans; D009271:Naltrexone / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D011957:Receptors, Opioid / Q000378:metabolism*; D014945:Wound Healing / Q000187:drug effects / Q000502:physiology
D000701:Analgesics, Opioid; D009292:Narcotic Antagonists; D011957:Receptors, Opioid; C033593:methionine-enkephalin receptor; D009271:Naltrexone
Brain Res Mol Brain Res. 1994 Jan;21(1-2):85-98
8164525
Arch Ophthalmol. 2006 Nov;124(11):1620-4
17102011
Endocrinology. 1985 Jan;116(1):328-31
3155453
Cornea. 2006 Jan;25(1):61-7
16331044
Diabetes. 1977 Aug;26(8):760-9
885298
Brain Res. 1998 Jul 6;798(1-2):254-60
9666142
Int J Oncol. 1999 May;14(5):991-8
10200353
Optometry. 2003 Jul;74(7):443-52
12877277
Cornea. 2005 Jul;24(5):614-9
15968171
Brain Res Brain Res Rev. 2002 Feb;38(3):351-76
11890982
N Engl J Med. 1993 Sep 30;329(14):977-86
8366922
Exp Eye Res. 1998 Sep;67(3):265-72
9778407
Arch Ophthalmol. 1977 Dec;95(12):2193-6
588113
Invest Ophthalmol Vis Sci. 1983 May;24(5):563-9
6841002
J Cell Biol. 1996 Dec;135(6 Pt 1):1669-77
8978831
J Ocul Pharmacol Ther. 2006 Oct;22(5):377-87
17076633
Brain Res. 2000 Nov 3;882(1-2):169-79
11056196
Lancet. 1985 Sep 28;2(8457):725-6
2863707
Diabetes Care. 2001 Mar;24(3):479-82
11289471
Diabetes. 1986 Oct;35(10):1143-51
2944783
Eur J Pharmacol. 2000 Aug 11;401(3):375-9
10936496
Brain Res Mol Brain Res. 1997 Jun;46(1-2):25-30
9191075
Neuropeptides. 2007 Dec;41(6):441-52
17910895
Cornea. 2008 Jun;27(5):565-73
18520507
Life Sci. 1982 Dec 27;31(26):2961-9
7162359
Graefes Arch Clin Exp Ophthalmol. 1989;227(2):142-4
2721983
J Cell Biol. 1983 Sep;97(3):849-57
6885921
Brain Res. 1998 May 4;792(1):72-8
9593829
Invest Ophthalmol Vis Sci. 2000 Sep;41(10):2915-21
10967045
Am J Physiol Regul Integr Comp Physiol. 2009 Sep;297(3):R844-52
19605761
Metabolism. 1992 May;41(5):460-1
1588823
Cornea. 2007 Oct;26(9 Suppl 1):S75-81
17881921
Cancer Res. 2007 Nov 1;67(21):10511-8
17974995
Am J Ophthalmol. 1983 Sep;96(3):368-71
6311017
Invest Ophthalmol Vis Sci. 1987 Feb;28(2):212-20
8591898
J Histochem Cytochem. 1996 Dec;44(12):1469-79
8985139
Arch Ophthalmol. 1983 Mar;101(3):469-71
6830506
Metabolism. 1987 Mar;36(3):286-9
3547015
Arch Ophthalmol. 1979 Jun;97(6):1076-8
444136
Metabolism. 1996 Sep;45(9):1065-8
8781292
Arch Ophthalmol. 2007 Aug;125(8):1082-8
17698755
Diabetes Care. 1997 Jul;20(7):1183-97
9203460
Jpn J Ophthalmol. 2002 Mar-Apr;46(2):130-9
12062217
J Ocul Pharmacol Ther. 2007 Apr;23(2):89-102
17444796
Brain Res Bull. 1991 Dec;27(6):805-8
1786557
Can J Ophthalmol. 1995 Apr;30(3):142-6
7627899
Curr Eye Res. 2003 May;26(5):249-62
12854052
Cornea. 2006 Aug;25(7):821-9
17068460
Metabolism. 1990 Apr;39(4):378-83
1691431
Ophthalmology. 1980 Mar;87(3):229-33
7191550
Exp Eye Res. 1980 Nov;31(5):611-21
6778708
Brain Res. 1999 Mar 20;822(1-2):149-63
10082893
Diabetes. 1982 Sep;31(9):789-94
6819173
Brain Res. 1995 Feb 6;671(1):105-11
7728521
Invest Ophthalmol Vis Sci. 2003 Sep;44(9):3802-9
12939295
JAMA. 1989 Feb 24;261(8):1155-60
2915437
Exp Eye Res. 2001 Aug;73(2):179-89
11446768
Diabetes. 2009 May;58(5):1077-85
19188434
Invest Ophthalmol Vis Sci. 2000 Feb;41(2):362-8
10670463
Ophthalmic Res. 1982;14(4):269-78
7133621
Am J Ophthalmol. 1978 May;85(5 Pt 1):651-5
655244
Am J Physiol. 1999 May;276(5):R1320-6
10233022
Ophthalmic Surg. 1991 Oct;22(10):565-9
1961612
Life Sci. 1998;62(24):2219-29
9627081
Eur J Pharmacol. 2000 Jul 7;399(2-3):161-4
10884515
Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3604-15
16186340
J Histochem Cytochem. 1998 Sep;46(9):1033-41
9705969
Prog Retin Eye Res. 2003 Mar;22(2):113-33
12604055
Diabetes. 2002 Oct;51(10):3055-62
12351447
J Neurosci. 1985 Apr;5(4):857-65
3981246
Arch Ophthalmol. 1978 Aug;96(8):1401-3
678179
Invest Ophthalmol Vis Sci. 2007 Feb;48(2):590-6
17251454
Int J Oncol. 2006 Jun;28(6):1577-83
16685459
Neurosci Lett. 1999 Feb 12;261(1-2):118-20
10081941
Mol Cancer. 2008 Jan 11;7:5
18190706
Exp Eye Res. 2004 Aug;79(2):263-74
15325573
J Invest Dermatol. 2000 Nov;115(5):778-87
11069614
Ophthalmic Surg. 1994 Nov-Dec;25(10):700-3
7898864
Int Ophthalmol Clin. 1998 Spring;38(2):1-10
9604734
Exp Eye Res. 2009 Nov;89(5):686-92
19576213
Am J Ophthalmol. 1980 Oct;90(4):463-8
6999881
Optometry. 2001 Nov;72(11):691-704
12363257
Neuropeptides. 1992 Jan;21(1):55-63
1738434
Proc Natl Acad Sci U S A. 1979 Jun;76(6):3010-4
379870
Invest Ophthalmol Vis Sci. 2000 Jan;41(1):73-81
10634604
Trans Am Ophthalmol Soc. 1981;79:180-99
7342400
Diabetes. 1987 Jul;36(7):808-12
3556280
J Pharmacol Exp Ther. 1998 Apr;285(1):63-70
9535995
JAMA. 1988 Nov 18;260(19):2864-71
3184351
Int Ophthalmol Clin. 1998 Spring;38(2):19-36
9604736
Neuropeptides. 2005 Oct;39(5):495-505
16169076
Brain Res Bull. 2007 Apr 2;72(1):18-24
17303503
Med Biol. 1982 Apr;60(2):53-60
6178909
Int Ophthalmol Clin. 1984 Winter;24(4):111-23
6500867
Brain Res. 2003 Mar 28;967(1-2):37-47
12650964
Metabolism. 1996 Feb;45(2):137-142
8596479
Brain Res. 1985 Jul 22;339(1):39-47
2992696
Graefes Arch Clin Exp Ophthalmol. 1991;229(3):254-7
1869062
N Engl J Med. 1995 May 4;332(18):1210-7
7700316
Invest Ophthalmol Vis Sci. 1990 Mar 1;31(3):436-9
2318583
Exp Eye Res. 2003 Aug;77(2):211-7
12873452
Curr Eye Res. 2003 Oct;27(4):197-203
14562170
Exp Eye Res. 1997 Mar;64(3):355-9
9196386
Am J Optom Physiol Opt. 1988 Mar;65(3):224-30
3284372
Int J Oncol. 2006 Aug;29(2):489-94
16820893
Arch Ophthalmol. 1988 Jul;106(7):916-9
3390054
Brain Res. 1997 Jun 6;759(1):92-102
9219867
Curr Eye Res. 2000 Aug;21(2):608-15
11148597
Diabetes. 2006 Apr;55(4):1141-7
16567540
Brain Res. 1998 Aug 24;803(1-2):61-8
9729280
Indian J Ophthalmol. 1987;35(5-6):16-36
3508767
J Clin Endocrinol Metab. 1979 Oct;49(4):649-51
383740
Vet Ophthalmol. 2003 Jun;6(2):131-4
12753614
Curr Opin Cell Biol. 1997 Oct;9(5):691-700
9330873
Brain Res. 1991 Mar 22;544(1):79-85
1649664
Arch Ophthalmol. 1988 Nov;106(11):1572-4
3056353
Am J Physiol. 1995 Apr;268(4 Pt 2):R942-50
7733405
Arch Ophthalmol. 1989 Oct;107(10):1520-3
2803103
Res Commun Mol Pathol Pharmacol. 1996 Jul;93(1):3-12
8865365
Brain Res. 1999 Aug 28;839(2):243-52
10519047
Brain Res. 1995 Jul 10;685(1-2):129-34
7583238
Mol Biol Cell. 2004 Dec;15(12):5242-54
15371548
Neuropeptides. 2003 Apr;37(2):79-88
12747939
Mol Biol Cell. 2009 Jan;20(1):319-27
18923142
Br J Ophthalmol. 2005 Mar;89(3):254-5
15722297
Am J Pathol. 2001 Feb;158(2):723-34
11159210
Exp Eye Res. 2003 Dec;77(6):653-64
14609553
Brain Res. 1992 Oct 2;592(1-2):101-5
1450902
Acta Diabetol. 1998 Apr;35(1):9-12
9625283
J Biomed Eng. 1993 Mar;15(2):106-12
8459687
Graefes Arch Clin Exp Ophthalmol. 1988;226(4):389-92
3169590